The PLTs modified with anti‐CD41a to precisely and effectively allow VP16 to target abnormally activated macrophages, thus realizing long‐lasting and precise treatment of HLH.[15, 23, 24] After successfully constructing anti‐CD41‐PLT‐VP16, we measured its ability to target and inhibit macrophage activity. The gene discussed is ITGA2B; the disease is hemophagocytic syndrome.